ZIVO BIOSCIENCE INC | 10-Q: FY2025 Q3 Revenue: USD 65.63 K

LB filings
2025.11.14 21:50
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 65.63 K.

EPS: As of FY2025 Q3, the actual value is USD -0.27.

EBIT: As of FY2025 Q3, the actual value is USD -1.005 M.

Segment Revenue

  • Total Revenue: For the three months ended September 30, 2025, total revenue was $65,625, an increase from $31,500 in the same period in 2024. For the nine months ended September 30, 2025, total revenue was $119,025, up from $67,220 in the same period in 2024.

Operational Metrics

  • Net Loss: The net loss for the three months ended September 30, 2025, was $1,033,056, compared to $2,268,597 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $6,884,474, compared to $11,783,451 in the same period in 2024.
  • Gross Margin: For the three months ended September 30, 2025, the gross margin was $21,288, compared to $9,450 in the same period in 2024. For the nine months ended September 30, 2025, the gross margin was $39,209, compared to $21,952 in the same period in 2024.
  • Operating Loss: The operating loss for the three months ended September 30, 2025, was $1,018,343, compared to $2,260,037 for the same period in 2024. For the nine months ended September 30, 2025, the operating loss was $6,860,003, compared to $11,765,478 in the same period in 2024.

Cash Flow

  • Operating Cash Flow: For the nine months ended September 30, 2025, net cash used in operating activities was $2,173,204, compared to $3,407,788 in the same period in 2024.

Unique Metrics

  • Research and Development Expenses: For the nine months ended September 30, 2025, research and development expenses were $3,452,336, compared to $2,891,452 in the same period in 2024. This includes $2,738,282 of amortization of expenses related to exchange agreements.

Future Outlook and Strategy

  • Core Business Focus: ZIVO Bioscience, Inc. plans to continue developing bioactive compounds derived from its proprietary algal culture, targeting diseases such as poultry coccidiosis and bovine mastitis. The company aims to seek strategic partners for late-stage development and commercialization of its products in key global markets.
  • Non-Core Business: The company is also focusing on developing its algal biomass as a functional food ingredient and nutritional enhancement for human and animal use, with plans to expand into the North American green powder food market.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.